Ensysce Biosciences Inc (ENSC)
0.5467
-0.01
(-2.13%)
USD |
NASDAQ |
Apr 25, 16:00
0.55
0.00 (0.00%)
After-Hours: 20:00
Ensysce Biosciences Free Cash Flow (Quarterly): -1.802M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -1.802M |
| September 30, 2023 | -2.263M |
| June 30, 2023 | -3.108M |
| March 31, 2023 | -3.607M |
| December 31, 2022 | -3.296M |
| September 30, 2022 | -6.714M |
| Date | Value |
|---|---|
| June 30, 2022 | -4.440M |
| March 31, 2022 | -3.437M |
| December 31, 2021 | -3.768M |
| September 30, 2021 | -3.825M |
| June 30, 2021 | -0.1323M |
| March 31, 2021 | -0.5171M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-6.714M
Minimum
Sep 2022
-0.1323M
Maximum
Jun 2021
-3.076M
Average
-3.366M
Median
Free Cash Flow (Quarterly) Benchmarks
| Processa Pharmaceuticals Inc | -2.124M |
| Omeros Corp | -34.94M |
| Relmada Therapeutics Inc | -10.25M |
| NeuroBo Pharmaceuticals Inc | -3.402M |
| MAIA Biotechnology Inc | -3.992M |